Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Go back to Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 5,146,218 | |||||
| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 5,146,218 | |||||
| Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) | Delayed: 17.88 -0.13 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.01 | 52 Week High | $26.24 | |||
| Open | $18.13 | 52 Week Low | $18.86 | |||
| Day High | $18.40 | P/E | N/A | |||
| Day Low | $17.81 | EPS | $0.00 | |||
| Volume | 104,923 | |||||
